Stock AMLX AMYLYX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Real-time Estimate Cboe BZX
Other stock markets
 01:29:40 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.765 USD +0.28% Intraday chart for Amylyx Pharmaceuticals, Inc. +2.62% -88.01%
May. 15 Transcript : Amylyx Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:40 AM
May. 14 Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:40 AM
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating
MT
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
BU
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
BU
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
BU
Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating
MT
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
BU
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CI
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
BU
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
BU
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders
PR
AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
BU
AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating
MT
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO, ALBRIOZA from the Market, Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMLX Stock
  4. News Amylyx Pharmaceuticals, Inc.